Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.

Exclusion Criteria

• •recurrent or metastatic NPC patients
• •histologically confirmed keratinizing carcinoma (WHO type I) of nasal pharynx
• •already received radiation or chemotherapy
• •pregnant or lactating women, or women of childbearing age without birth control
• •HIV (+)
• •had other cancers before
• •used immune checkpoint inhibitor(CTLA-4、PD-1、PD-L1 etc.) before
• •complications requiring long-term treatment with immunosuppressive drugs or systemic or local use of corticosteroids with immunosuppressive dose
• •with immune deficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma in childhood who have completely relieved and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators cannot be included)
• •use of massive dose of glucocorticoids within 4 weeks before enrollment
• •laboratory test values do not meet relevant standards within 7 days before enrollment
• •significantly lower functions of heart, liver, lung, kidney and bone marrow
• •serious or uncontrolled medical diseases or infections
• •participating other clinical trial in the same time
• •HBsAg (+) and HBV DNA \>1×10E3 copiers /mL
• •HCV (+) unless HCV RNA PCR(-)
• •with any other treatment contraindications